Stock Analysis, Dividends, Split History

MYL / Mylan N.V. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price37.21
Volume3,185,900.00
Market Cap ($M)19,323.46
Enterprise Value ($M)21,689.96
Book Value ($M)12,208.70
Book Value / Share23.68
Price / Book1.58
NCAV ($M)-14,765.00
NCAV / Share-28.64
Price / NCAV-1.31
Share Statistics
Common Shares Outstanding 514,781,709
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Assets33,271.50
Liabilities21,062.80
Quick Ratio0.77
Current Ratio1.29
Income Statement (mra) ($M)
Sales Revenue Goods Gross0.00
Sales Revenue Goods Net11,760,000,000.00
Sales Revenue Grosstonetadjustments0.00
Sales Revenue Net11,907,700,000.00
Other Sales Revenue Net147,700,000.00
Operating Income1,437.10
Net Income696.00
Earnings Per Share Diluted1.30
Earnings Per Share Basic1.30
Cash Flow Statement (mra) ($M)
Cash From Operations2,064.80
Cash from Investing-905.40
Cash from Financing-905.40
Identifiers and Descriptors
CUSIPN59465109
Central Index Key (CIK)1623613
Related CUSIPS
010235618 628530957 N59465959 062853010 001103120 0N5946510 N59465909 628530907

Split History

Stock splits are used by Mylan N.V. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

It May Be Better To Avoid Sanofi

2018-09-06 seekingalpha
Since September 5, 2017, Sanofi (NYSE:SNY) stock has been down by almost 15%. And most of this downfall stems from investors concerned about the company’s future growth trajectory, considering that its top-selling diabetes drug Lantus, which was earning as much as $7.0 billion annually, went off-patent in 2015. Another blockbuster drug, Plavix, also went off-patent in 2012. (14-0)

Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany

2018-09-03 seekingalpha
Discussion: AstraZeneca (AZN) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE). The drug failed to achieve a statistically valid reduction in disease activity at month 12 as measured by a scale called SRI4. Reduction in SRI4 value was the primary endpoint of the trial. Shares slipped marginally by 1% in the negative news. (28-0)

9 High-Risk Stocks to Buy for Massive Rewards

2018-08-31 investorplace
Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues. (135-4)

Why Teva’s Outlook Is Mixed

2018-08-23 investorplace
Teva Pharmaceutical (NYSE:TEVA) perfectly illustrates the dangers of trading volatile biotech stocks. Last year was particularly horrendous for TEVA stock. The company’s shares lost almost half their market value. It was also one of those stories that got worse as you read more about it. (19-3)

Your Daily Pharma Scoop: Audentes's New Designation, Esmya Rejected, Agilent Approved

2018-08-23 seekingalpha
Discussions: Audentes Therapeutics' (BOLD) AT132 receives FDA designation of a Regenerative Medicine Advanced Therapy (‘RMAT). The therapy is indicated for treatment of X-linked myotubular myopathy (‘XLMTM). RMAT is in many ways similar to the Breakthrough Therapy status and allows accelerated review of a drug along with more frequent interaction with the FDA during the development stage. The therapy has already acquired Rare Pediatric disease, Fast track and Orphan Drug Designation in the U. (24-1)

CUSIP: N59465109